Lilly Collaborates with AC Immune (AC) to Develop Candidates for Neurodegenerative Diseases
Lilly Collaborates with AC Immune (AC) to Develop Candidates for Neurodegenerative Diseases
Shots:
- AC Immune to receive $80M upfront, $1760M milestones and royalties on sales and Lilly to get WW commercialization rights for AC Immune’s tau aggregation inhibitors and will invest $50M as convertible notes in AC. AC to initiate P-I study for Morphomer inhibitors and Lilly to fund the trial
- The focus of the agreement is to develop AC Immune’s candidate, ACI-302 by combining AC Immune’s Morphomer technology with Lilly’s development technology
- Morphomer inhibitors are indicated for reduction of toxic intracellular misfolded and aggregated tau indicated for Alzheimer’s disease (AD) and multiple neurodegenerative diseases
Click here to read full press release/ article | Ref: Eli Lilly | Image: Wall Street Journal